EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study

Geetha Beauchamp iD, Sybil Hosek, Deborah J Donnell, Kwun C G Chan, Brian P Flaherty iD, Peter L Anderson, Bonnie J Dye, Nyaradzo Mgodi, Linda-Gail Bekker, Sinead Delany-Moretlwe, Connie Celum, HPTN 082 study team

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Geetha Beauchamp und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Systems and Population Health, University of Washington, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Acquired Immunodeficiency Syndrome, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

African adolescent girls and young women (AGYW) represent a large proportion of new HIV infections, a priority population for pre-exposure prophylaxis (PrEP), but adherence remains a challenge. A reliable, valid readiness tool would help identify AGYW motivated to take PrEP who need adherence support.

Methods

In the HPTN 082 open-label PrEP study (2016–2019), South African and Zimbabwean women ages 16–25 were administered an HIV prevention readiness measure (HPRM). The 25 items in the HPRM included medication beliefs, connection with care, disclosure of PrEP use, social support, and housing stability using a 5-point Likert scale. Exploratory factor analysis (EFA) using polychoric correlations, scale reliability, and predictive validity were performed on data from 315 participants who responded to all items. We assessed the predictive value of HPRM scores with PrEP adherence, defined as tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots, as a continuous measure and dichotomized as high PrEP adherence (≥700 fmol/punch).

Results

EFA yielded 23 items with three subscales: self-efficacy (16 items), PrEP disclosure (4 items), and social support (3 items). Cronbach’s α ranged from 0.71 to 0.92 for the overall scale and the subscales. The average overall scale and the subscales were predictive of 3-month PrEP adherence for TFV-DP concentrations: for each unit increase of the HPRM score, TFV-DP concentration increased by 103 fmol/punch (95% CI: 16, 189, p = 0.02); the highest HPRM score equated with 608 fmol/punch on average. For the self-efficacy subscale, TFV-DP increased by 90 fmol/punch (95% CI: 7, 172, p = 0.03); PrEP disclosure, 68 fmol/punch (95% CI: 19, 117 p = 0.01); and social support, 58fmol/punch (95% CI: 2, 113, p = 0.04). Higher PrEP disclosure suggests high adherence (OR 1.36, 95% CI: 1.00, 1.86, p = 0.05) and predicted persistent high adherence at both months three and six (OR: 1.50, 95% CI: 1.03, 2.21, p = 0.04).

Conclusions

The HPRM scale overall and the subscales individually demonstrated good internal consistency among African young women. PrEP disclosure subscale exhibiting significant association with persistent high PrEP adherence is an important finding for PrEP adherence support programs. Future work will assess replicability and expand self-efficacy and social-support subscales after item revision.

Trial registration

ClinicalTrials.gov NCT02732730 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsAcquired Immunodeficiency SyndromePre-Exposure ProphylaxisHumansFemaleAdolescentYoung AdultAdultHIVReproducibility of ResultsMedication AdherenceAdenineOrganophosphates

Substanzen

Anti-HIV Agentstenofovir diphosphateAdenineOrganophosphates

Autor:innen und Institutionen

  • Department of Health Systems and Population Health, University of Washington, Seattle, Washington, United States of America.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Department of Psychiatry, Stroger Hospital of Cook County, Chicago, Illinois, United States of America.
  • Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
  • Department of Psychology, University of Washington, Seattle, Washington, United States of America.
  • Department of Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, United States of America.

ORCID-Profile: Geetha Beauchamp, Brian P Flaherty

Förderung

  • NIAID NIH HHS
  • NIMH NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Beauchamp, G., Hosek, S., Donnell, D. J., Chan, K. C. G., Flaherty, B. P., Anderson, P. L., Dye, B. J., Mgodi, N., Bekker, L. G., Delany-Moretlwe, S., Celum, C., & HPTN 082 study team (2023). Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study. PLOS ONE. https://doi.org/10.1371/journal.pone.0281728

Vancouver

Beauchamp G, Hosek S, Donnell DJ, Chan KCG, Flaherty BP, Anderson PL, et al. Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study. PLOS ONE. 2023. doi:10.1371/journal.pone.0281728

BibTeX
@article{Beauchamp2023,
  author = {Beauchamp, Geetha and Hosek, Sybil and Donnell, Deborah J and Chan, Kwun C G and Flaherty, Brian P and Anderson, Peter L and Dye, Bonnie J and Mgodi, Nyaradzo and Bekker, Linda-Gail and Delany-Moretlwe, Sinead and Celum, Connie and HPTN 082 study team, HPTN 082 study team},
  title = {Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281728}
}
Kostenlos starten →